Emerging Cancer Vaccine Market Poised to Surpass $8 Billion by 2012

New York, November 13, 2006— The emergence of vaccines to both prevent and treat the escalating worldwide incidence of cancer is one of the most highly anticipated pharmaceutical breakthroughs of the new millennium. And according to new analyses released today from market research firm Kalorama Information, the potential for the cancer vaccine market to grow from an estimated $481 million in 2007 to more than $8 billion by 2012 is very real.

According to The Emerging Cancer Vaccine Market, several promising vaccines are in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. It is expected that the market will see as many as five approvals by 2008 alone resulting in nearly $700 million in potential new cancer vaccine revenues.

By 2012, eight additional approvals are possible, which could result in exponential market growth. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products.

Yet in many ways the market must fight against itself as it struggles to overcome fallout from strong prospects which have previously met with developmental delays and failures.

“Each vaccine will have to prove itself as being highly efficacious, reasonably cost-effective, and able to achieve widespread physician approval,” notes Melissa Elder, the report’s author. “Despite the enormous relief potential for mankind, vaccine manufacturers will have to demonstrate that the new vaccines are superior to currently established treatment protocols in order for insurers to accept them for reimbursement, thus making them accessible to the masses.”

This highly anticipated 2nd Edition of The Emerging Cancer Vaccine Market chronicles the technological, clinical, and business trends shaping this emerging field in regards to cervical, colorectal, prostate, and lung cancers, melanoma, lymphoma, and others. It includes research and development pipelines, in-depth company profiles, market forecasts and more. It is available from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1190824.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific market research reports, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.